Endo Pharmaceuticals Holdings Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).

Endo Pharmaceuticals Holdings Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For quarter, the company reported total revenues of $361,027,000, operating income of $84,314,000, income before income taxes of $79,329,000, net income of $49,422,000 or $0.42 diluted per share compared with total revenues of $316,768,000, operating income of $107,327,000, income before income taxes of $105,917,000, net income of $65,994,000 or $0.55 diluted per share over the same period last year. Adjusted total revenues were $361,027,000, adjusted operating income was $386,447,000, adjusted income before income taxes was $115,010,000, adjusted net income of $74,251,000 or $0.63 diluted per share compared with adjusted total revenues of $316,768,000, adjusted operating income of $124,339,000, adjusted income before income taxes of $126,540,000, adjusted net income of $78,724,000 or $0.66 diluted per share over the same period last year. For nine months, the company reported total revenues of $1,069,435,000, operating income of $226,696,000, income before income taxes of $204,112,000, net income of $118,488,000 or $1.01 diluted per share, net cash provided by operating activities of $219,015,000 compared with total revenues of $913,200,000,operating income of $274,544,000, income before income taxes of $283,671,000, net income of $182,650,000 or $1.45 diluted per share, net cash provided by operating activities of $228,109,000 over the same period last year. Adjusted total revenues of $1,069,435,000, adjusted operating income of $386,447,000, adjusted income before income taxes of $368,532,000, adjusted net income of $239,141,000 or $2.04 diluted per share compared with adjusted total revenues of $913,200,000, adjusted operating income of $327,543,000, adjusted income before income taxes of $343,290,000, adjusted net income of $219,638,000 or $1.74 diluted per share over the same period last year. The company provided earnings guidance for the full year ending December 31, 2009. For the period the company estimates total revenues to be between $1.440 billion and $1.465 billion. The company also now estimates reported (GAAP) diluted earnings per share to be between $1.41 and $1.47, and this EPS increase is primarily due to changes in the fair value of contingent consideration associated with the Indevus transaction partially offset by the addition of milestone payments associated with the company's recent deal with ProStrakan to in-license FORTESTA(TM). Adjusted diluted earnings per share are now estimated to be between $2.67 and $2.73.

Endo Pharmaceuticals Holdings Inc. established a $300 million, three-year senior secured revolving credit facility, the terms of which are set forth in a Credit Agreement dated as of October 16, 2009 among the company, the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, Barclays Capital as syndication agent, and J.P. Morgan Securities Inc. and Barclays Capital as joint book runners and joint lead arrangers. The credit facility will be available for letters of credit, working capital and general corporate purposes. The credit agreement provides that with respect to the credit facility up to $20 million of U.S. dollar equivalent is available for letters of credit and up to $20 million is available for swing line loans on same-day notice. The credit agreement also permits up to $100 million of additional revolving or term loan commitments from one or more of the existing lenders or other lenders (with the consent of the Administrative Agent) without the need for consent from any of the existing lenders under the Credit Facility.